About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Eurasian Hematology-Oncology Group
http://www.ehog.net/
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Videos
8th Eurasian Hematology Oncology Summit
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Palliative & Supportive Care
COVID-19
Basic Science
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Lung
Business
7th Eurasian Hematology Oncology Summit
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Xth Eurasian Hematology-Oncology Congress
Breast
Lung
Hematologic Oncology
Gastrointestinal
Genitourinary
General Oncology
Sarcoma
Skin
Head & Neck
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
R
CML Highlights: Has Molecular Monitoring Replaced Cytogenetic Monitoring? Is Imatinib Effective Initial Treatment in Chronic Phase? Are High-Risk ACA Associated With Reduced Survival?
By
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
FEATURING
Rudiger Hehlmann
By
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
FEATURING
Rudiger Hehlmann
9 views
January 12, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Leukemia
18:13
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Pre-Pandemic CML Treatment: What Is CGA? How Do Ponatinib, Nilotinib…
Feat.
P. Raanani
19:37
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Challenges in Treatment of Leukemias and Bone Marrow Failure in Deve…
Feat.
K. Rashid
23:29
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
AML Treatment in Developing Countries: LIMC vs. HIC Differences - St…
Feat.
E. Rego
15:57
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Cytogenetic Characterization in AML: How Do Gene Mutations Impact Ov…
Feat.
M. Yilmaz
35:51
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Targeted Therapy for Older Patients With AML: Is Addition of GO to I…
Feat.
C. Schiffer
18:11
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
State of the Art in Adults With ALL: Salvage & 1L Ino and Blina …
Feat.
E. Jabbour
14:29
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
How I Manage CML at MD Anderson in 2020: Are 1L Therapies Getting Be…
Feat.
E. Jabbour
17:01
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Pediatric ALL Updates: What Is the COG Risk Stratification Approach?…
Feat.
S. Anak
16:00
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
ALL Highlights: Should We De-Escalate Chemo? Do TKIs (Dasatinib, Nil…
Feat.
D. Hoelzer
23:41
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Ph+ and Ph-Like Adult Frontline ALL: What Is the Optimal Strategy in…
Feat.
R. Foa
19:05
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
CAR-T in Pediatric ALL: Tisagenlecleucel in B-Cell Disease, CAR-T vs…
Feat.
F. Saglio
30:27
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
CML Highlights: Has Molecular Monitoring Replaced Cytogenetic Monito…
Feat.
R. Hehlmann
28:52
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Molecular Monitoring and CML: What Is the Influence on Therapy and H…
Feat.
N. Chaudhri
31:57
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Recommendations for Treatment Discontinuation in CML: Is TFR Feasibl…
Feat.
C. Fava
11:53
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
CML Updates: Prognostic Factors, Conventional Drugs, 1L Therapy, Tre…
Feat.
W. Sattar
12:50
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
19 y/o Male With Jaundice and a Duodenal Ampulla Tumor: Does Standar…
Feat.
M. Merter
15:31
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
AML Updates: Can CC-486 Improve OS in 1st Remission in Older Patient…
Feat.
G. Garcia-Manero
20:42
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
AML Highlights: Do Gilteritinib & Quizartinib Prolong OS in FLT3…
Feat.
G. Martinelli
